Endovia Health Sciences Inc(EDVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 21 at 7:56 PM ET (Korea 10/22 08:56)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -68.97 | Insider Own | 0.01% | Shs Outstand | 11.1M | Perf Week | 9.21% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 11.1M | Perf Month | -33.65% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 2.75% | Short Float | 1.57% | Perf Quarter | -59.14% |
| Income | -0.03B | P/S | 1.67 | EPS this Y | - | Inst Trans | 1.07% | Short Ratio | 0.04 | Perf Half Y | -90.76% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -201.4% | Short Interest | 0.17M | Perf YTD | -94.46% |
| Book/sh | -3.82 | P/C | 7.08 | EPS past 3/5Y | 19.99% 42.21% | ROE | - | 52W High | -98.86% ($13.40) | Perf Year | -97.98% |
| Cash/sh | 0.02 | P/FCF | - | Sales past 3/5Y | -84.07% -49.84% | ROIC | - | 52W Low | 13.84% ($0.13) | Perf 3Y | -99.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 65.38% | Gross Margin | -191.86% | Volatility(W/M) | 9.13% 12.94% | Perf 5Y | -99.94% |
| Dividend TTM | - | EV/Sales | 7.69 | Sales Y/Y TTM | -83.63% | Oper. Margin | -1463.75% | ATR (14) | 0.02 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.03 | EPS Q/Q | 91.47% | Profit Margin | -3033.6% | RSI (14) | 35.86 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.03 | Sales Q/Q | -100% | SMA20 | -4.65% ($0.16) | Beta | -1.12 | Target Price | $160 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/20 | SMA50 | -39.27% ($0.25) | Rel Volume | 0.14 | Prev Close | $0.14 |
| Employees | 2 | LT Debt/Eq | - | EPS/Sales Surpr. | - -53.24% | SMA200 | -87.32% ($1.18) | Avg Volume(3M) | 4.68M | Price | $0.15 |
| IPO | 2019/2/5 | Option/Short | No/Yes | Trades | 174 | Volume | 639,444 | Change | 5.52% |
� Originally started as a beverage business and has now pivoted into a cannabinoid-based health and wellness platform. This US-listed company is restructuring its operations around three core pillars: pharmaceutical assets, veterinary therapeutics, and consumer wellness beverages. It is a micro-cap stock listed on a US stock exchange.
Over the past 1 year, on the lower side
99% below its 1-year high.
Traded less than usual. That is 14% of its average volume.
EDVA has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $167. Peers typically go for $1,173.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.8%.
Tap to view numbers
It ranks #583 of 595 in the industry
Based on market cap of $2M.
OGEN#580 Oragenics Inc $2M PER - 
VRAX#582 Virax Biolabs Group Ltd $2M PER - EDVA#583 Endovia Health Sciences Inc $2M PER - 
XRTX#584 XORTX Therapeutics Inc $2M PER - 
GNPX#585 Genprex Inc $2M PER - 
FAQ
What kind of company is EDVA?
EDVA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EDVA?
The market cap of EDVA is approximately $2M, ranking 5,827 within its sector.
What is the 52-week high and low for EDVA?
EDVA has recorded a 52-week high of $13.40 and a low of $0.13.
